Summary & Overview
CPT 82233: Beta–Amyloid 40 Assay, Laboratory Chemistry
CPT code 82233 represents a laboratory chemistry assay for beta–amyloid 40, a protein biomarker linked to Alzheimer’s disease pathology. As interest in biomarker-driven diagnosis and monitoring of neurodegenerative conditions increases, assays such as this are becoming more clinically relevant for research settings and specialty diagnostic workflows. The code captures the analytic component of measuring beta–amyloid 40 in a clinical laboratory setting.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national-level overview of clinical context for beta–amyloid 40 testing, the typical laboratory service setting, and which payers commonly adjudicate claims for biomarker assays. The publication outlines benchmarks and coverage considerations where available, highlights coding context for laboratory chemistry assays, and summarizes policy and clinical implications for stakeholders in diagnostics, neurology, and laboratory services.
This report is intended to inform providers, billing specialists, and policy analysts about the clinical purpose of CPT code 82233, payer coverage landscape, and the types of insights available on utilization and reimbursement for beta–amyloid 40 testing. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 82233 describes a laboratory chemistry test measuring beta–amyloid 40, a biomarker associated with Alzheimer’s disease. The service involves analysis by a clinical laboratory professional to quantify beta–amyloid 40 levels in patient specimens.
Service type: Laboratory chemistry/biomarker assay
Typical site of service: Clinical laboratory or hospital laboratory
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 72-year-old patient with progressive cognitive decline and memory impairment is evaluated in a neurology clinic for possible Alzheimer’s disease. The neurologist orders cerebrospinal fluid (CSF) or plasma biomarker testing including beta-amyloid 40 to help characterize amyloid pathology as part of a multimodal diagnostic workup. A phlebotomy or lumbar puncture is performed in an outpatient infusion suite or hospital procedure area; specimens are sent to a clinical laboratory. The laboratory analyst performs the quantitative chemistry assay for 82233 (beta-amyloid 40). Results are reviewed by the ordering neurologist and integrated with clinical exam, neuroimaging, and other CSF biomarkers (for example, beta-amyloid 42, total tau, phosphorylated tau) to inform diagnostic formulation and care planning. Typical sites of service include hospital outpatient laboratories, independent diagnostic laboratories, and specialty clinic labs within academic medical centers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Applied when no additional modifier is required. |
26 | Professional component |